

Autifony Therapeutics wins Best Emerging Biotech Award at OBN Awards Dinner

London, UK – 2nd October 2013 - Autofony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders and serious disorders of the nervous system, announced that it was awarded the prize for Best Emerging Biotech at the OBN Annual Awards Dinner on 1st October.

The award was presented by James Cowper and collected by John Berriman, Chairman of Autofony. John Berriman commented: “We are delighted and honoured that Autofony has been recognised with the OBN award for Best Emerging Biotech. This past year has been one of major progress for Autofony, with entry into Phase I clinical trials of our first-in-class Kv3 channel modulator lead programme for hearing disorders, an additional £5.5 million in equity funding and a Technology Strategy Board Biomedical Catalyst Early Stage award to investigate our Kv3 channel modulation approach in schizophrenia, a completely novel mechanism, with a differentiated molecule. We look forward to further exciting progress in the year ahead.”



- ENDS -

About Autofony Therapeutics Ltd

Autifony Therapeutics is an independent UK based biotechnology company formed in 2011 as a spin-out from GSK, which retains equity in the company. The company is focused on the development of high value, novel medicines to treat hearing disorders and serious disorders of the central nervous system. Autofony Therapeutics is funded by SV Life Sciences, Imperial Innovations, Pfizer Venture Investments, International Biotechnology Trust PLC and UCL Business. www.autifony.com

For more information, please contact: Dr Charles Large, Chief Scientific Officer, **Email:** charles.large@autifony.com